SUTENT is a kinase inhibitor indicated for the treatment of • Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • Advanced renal cell carcinoma (RCC). • Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of SUTENT (sunitinib malate) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the SUTENT (sunitinib malate) medicine cost price in India.
The order for SUTENT (sunitinib malate) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications
SUTENT® (sunitinib malate) capsules, oral Initial U.S. Approval: 2006
Generic Name: sunitinib malate
Capsules: 12.5 mg, 25 mg, 50 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand SUTENT (sunitinib malate) on prescription and Import License in Patient's Name only.
For overseas patients, SUTENT (sunitinib malate) can be made available in Send your enquiry to find SUTENT (sunitinib malate) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For SUTENT (sunitinib malate) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA expands approval of Sutent to reduce the risk of kidney cancer returning For More Details
Immunotherapy Brings More Options for Frontline RCC Treatment For More Details